Breaking News

Glaxo to Pay $488.7 Million Fine to End China Corruption Probe
Tweet TWEET

Illumina Expands Product Portfolio to Support Oncology Clinical Research and Discovery

  Illumina Expands Product Portfolio to Support Oncology Clinical Research and   Discovery       End-to-End Genomics Solutions Will Transform the Future of Oncology  Business Wire  SAN DIEGO -- April 2, 2014  Illumina, Inc. (NASDAQ:ILMN) today announced new products that can be applied directly to the discovery and translation of genomic variation in blood and tissue associated with cancer. The expanded portfolio leverages the company’s industry-leading next-generation sequencing (NGS) and microarray scanning systems to deliver sample-to-data solutions for basic and clinical cancer research.  New Product Additions  The following products complement the company’s existing NGS and array portfolio and support efficient and streamlined workflows for cancer research and other applications using Illumina’s NGS sequencers, including the newly launched NextSeq™ 500 sequencing system.    *TruSeq® RNA Access Library Prep Kits offer a reproducible, economical     solution for analyzing RNA isolated from formalin-fixed, paraffin-embedded     (FFPE) tissues, and other low-quality samples. Starting with as little as     10 ng total RNA, the kits deliver the discovery power of RNA sequencing at     a reduced cost by focusing on the coding regions of the transcriptome. The     kits will begin shipping this month. In addition, the kits will be     available on the NeoPrep^TM Library Prep System in 2H 2014.   *TruSight™ Myeloid Sequencing Panel uses expert-curated content to offer     accurate, efficient, and cost-effective identification of somatic     mutations in myeloid malignancies. It provides an assessment of 54     critical genes, including tumor suppressor genes and hotspots in     oncogenes. This fully integrated DNA-to-data solution offers a streamlined     workflow and automated data analysis with somatic variant calling. The     panel will begin shipping in Q2 2014.   *New BaseSpace® Core Apps  offer informatics support for the cancer market.     The TopHat and Cufflinks Apps, as well as the RNA Express App, are     designed to support transcriptome data analysis, including detection of     fusion genes critical in cancer research. A Tumor Normal App delivers     somatic variant calling of tumor and matched normal whole genome data sets     based on the accurate Strelka method. In addition, Illumina is developing     apps to analyze data from Illumina’s TruSight Tumor Sequencing Panel and     TruSeq Amplicon - Cancer Panel, as well as an exome version of the Tumor     Normal App that delivers variants (including copy number variations) based     on Nextera® Rapid Capture Enrichment data. The RNA-Seq and Tumor Normal     Apps will be available early this month in BaseSpace, and the others will     be available later in 2014.  “The adoption of a precision cancer medicine, a clinical paradigm based on genetic assessment of a patient’s cancer, is rapidly occurring,” said Hanlee Ji, an Assistant Professor of Medicine at Stanford University and Senior Associate Director of the Stanford Genome Technology Center. “As a physician-scientist who is actively developing and applying novel sequencing approaches in the clinical oncology setting, Illumina’s NGS systems are instrumental tools. The advances in NGS with improved sequence quality and dramatic reduction in cost will continue to enable progress in oncology and genomic medicine.”  “The latest additions to our product portfolio address the unique needs of oncology researchers,” said Rick Klausner, M.D., Chief Medical Officer of Illumina. “Our product solutions now support library preparation of the low-input, poor-quality archival tissue samples that are so valuable for cancer research. We’re accelerating the discovery of cancer-associated variants with simple-to-use data analysis solutions, including software tools that support the creation of genotypic/phenotypic databases. Our goal is to expand the use of NGS beyond basic research, delivering relevant oncological genomic information to clinical researchers where it has the potential to inform improvements in cancer care.”  For more information about Illumina’s oncology portfolio, visit www.illumina.com/cancersolutions.  About Illumina  Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.  Forward-Looking Statements  This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability and shipping dates for new products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.  Contact:  Illumina, Inc. Investors: Rebecca Chambers 858-255-5243 rchambers@illumina.com or Media: Jennifer Temple 858-882-6822 pr@illumina.com  
Press spacebar to pause and continue. Press esc to stop.